Patents Represented by Attorney, Agent or Law Firm J. Antonio Garcia-Rivas
-
Patent number: 6692764Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by wet granulation tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease. These compositions are prepared without the addition of binder; instead, the drug itself acts as a binder.Type: GrantFiled: September 23, 2002Date of Patent: February 17, 2004Assignee: Merck & Co., Inc.Inventors: Ashok V. Katdare, Kenneth A. Kramer
-
Patent number: 6632836Abstract: The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.Type: GrantFiled: October 21, 1999Date of Patent: October 14, 2003Assignee: Merck & Co., Inc.Inventors: Robert K. Baker, Jianming Bao, Jennifer Chee, Maria L. Garcia, Gregory J. Kaczorowski, Frank Kayser, Andrew Kotliar, Chou Juitsai Liu, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht, William A. Schmalhofer, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
-
Patent number: 6632818Abstract: The present invention is directed to piperazine-containing macrocyclic compounds which inhibit prenylyl-protein transferase, such as farnesyl-protein transferase (FTase), and therefore inhibit the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.Type: GrantFiled: January 8, 2001Date of Patent: October 14, 2003Assignee: Merck & Co., Inc.Inventor: Christopher J. Dinsmore
-
Patent number: 6586424Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: February 1, 2002Date of Patent: July 1, 2003Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
-
Patent number: 6586423Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: February 1, 2002Date of Patent: July 1, 2003Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
-
Patent number: 6544967Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.Type: GrantFiled: January 8, 2001Date of Patent: April 8, 2003Assignee: Merck & Co., Inc.Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
-
Patent number: 6517867Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Type: GrantFiled: October 19, 2001Date of Patent: February 11, 2003Assignee: Merck & Co., Inc.Inventors: Simon R. Bechard, Kenneth A. Kramer, Ashok V. Katdare
-
Patent number: 6465443Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.Type: GrantFiled: March 20, 2001Date of Patent: October 15, 2002Assignee: Merck & Co., Inc.Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
-
Patent number: 6432932Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.Type: GrantFiled: September 2, 1999Date of Patent: August 13, 2002Assignee: Merck & Co., Inc.Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
-
Patent number: 6406714Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Type: GrantFiled: October 17, 2000Date of Patent: June 18, 2002Assignee: Merck & Co., Inc.Inventors: Simon R. Bechard, Kenneth A. Kramer, Ashok V. Katdare
-
Patent number: 6387903Abstract: The present invention is directed to compounds which inhibit prenyl-protein transferases, farnesyl-protein transferase and geranylgeranyl-protein transferase type I, and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I and the prenylation of the oncogene protein RAS.Type: GrantFiled: February 1, 2000Date of Patent: May 14, 2002Assignee: Merck & Co., Inc.Inventors: Christopher J Dinsmore, John H. Hutchinson, Theresa M. Williams
-
Patent number: 6380203Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.Type: GrantFiled: November 18, 1999Date of Patent: April 30, 2002Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino
-
Patent number: 6313138Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: February 20, 2001Date of Patent: November 6, 2001Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hartman
-
Patent number: 6306874Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: October 17, 2000Date of Patent: October 23, 2001Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
-
Patent number: 6303637Abstract: The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.Type: GrantFiled: October 21, 1999Date of Patent: October 16, 2001Assignee: Merck & Co., Inc.Inventors: Jianming Bao, Andrew Kotliar, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
-
Patent number: 6265403Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy, and the like in mammals.Type: GrantFiled: January 7, 2000Date of Patent: July 24, 2001Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, Randall W. Hungate, Andrew J. Tebben
-
Patent number: 6248756Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferas (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: February 11, 1999Date of Patent: June 19, 2001Assignee: Merck & Co., Inc.Inventors: Neville J. Anthony, Christopher Dinsmore, Robert P. Gomez, John H. Hutchinson, John S. Wai, Theresa M. Williams, Ian M. Bell, Mark W. Embrey, Thorsten E. Fisher
-
Patent number: 6245759Abstract: The present invention relates to pyrazolo-pyrimidinyl compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: March 7, 2000Date of Patent: June 12, 2001Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate
-
Patent number: 6235741Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.Type: GrantFiled: May 28, 1998Date of Patent: May 22, 2001Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino, Mark E. Fraley
-
Patent number: 6228871Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.Type: GrantFiled: June 29, 1999Date of Patent: May 8, 2001Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, Randall W. Hungate, William F. Hoffman, William R. Huckle, Richard L. Kendall, Kenneth A. Thomas, Jr.